Latest Breaking News On - Ann arbor based esperion therapeutics - Page 1 : comparemela.com

Esperion believes it is entitled to $300 million in milestone payments after a study showed NEXLETOL reduced certain major adverse cardiovascular events by as much as 15 percent and the risk of heart attack by 23 percent.

Daiicho sankyo europeDaiichi sankyo europe gmbRoger newtonDaiicho sankyoExchange commissionPfizer incAnn esperion therapeutics incAnn arbor based esperion therapeuticsDaiichi sankyo europe gmbhEuropean economic area